{"filing":{"accession_number":"0001600620-26-000053","cik":"0001600620","ticker":"AUPH","company_name":"Aurinia Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"auph-20260603.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1600620/000160062026000053/auph-20260603.htm"},"events":[{"id":6945,"run_id":6089,"accession_number":"0001600620-26-000053","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a clear disclosure of shareholder voting results from Aurinia's annual general meeting held June 3, 2026. The filing reports final voting tallies for three proposals: election of five board directors (Proposal 1), appointment of PricewaterhouseCoopers LLP as independent auditor (Proposal 2), and advisory approval of executive compensation (Proposal 3), with detailed vote counts and percentages for each. This is a quintessential Item 5.07 shareholder_vote_results event.","company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4495,"accession_number":"0001600620-26-000053","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Aurinia's annual general meeting held June 3, 2026. The filing reports final voting tallies for three proposals: election of five board directors (Proposal 1), appointment of PricewaterhouseCoopers LLP as independent auditor (Proposal 2), and advisory approval of executive compensation (Proposal 3), with detailed vote counts and percentages for each. This is a quintessential Item 5.07 shareholder_vote_results event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:23:20.496616+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4495,"accession_number":"0001600620-26-000053","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a clear disclosure of shareholder voting results from Aurinia's annual general meeting held June 3, 2026. The filing reports final voting tallies for three proposals: election of five board directors (Proposal 1), appointment of PricewaterhouseCoopers LLP as independent auditor (Proposal 2), and advisory approval of executive compensation (Proposal 3), with detailed vote counts and percentages for each. This is a quintessential Item 5.07 shareholder_vote_results event.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T05:23:20.496616+00:00","company_name":"Aurinia Pharmaceuticals Inc.","ticker":"AUPH","filing_date":"2026-06-04"}]}